Recipharm Venture Fund

Carl-Johan Spak serves as CEO of Recipharm Venture Fund AB, a role he holds alongside his position as EVP of Development & Technology at Recipharm AB. That dual role means investment decisions are made with a direct line to the parent group's technology roadmap and commercial leadership. The fund's governance is integrated into Recipharm's wider corporate structure rather than operating as an independent LP vehicle.

The fund sources deal flow through the parent CDMO's commercial and technical teams, who work directly with biotech and pharma sponsors across more than 30 manufacturing facilities. Because Recipharm manufactures products for 8 of the top 10 global pharmaceutical companies, the fund has early visibility into emerging formulation, device, and processing challenges that create investment opportunities. The Nordic life-science network, including membership in SwedenBIO, provides an additional origination channel.

Recipharm Venture Fund operates as a corporate venture arm, investing off the parent company's balance sheet rather than raising capital from third-party limited partners. Following EQT's acquisition of Recipharm AB in 2021, the fund's investment capital is ultimately tied to the private equity sponsor's capital structure. The fund does not disclose the size of its committed capital or targeted deployment pace.

Portfolio companies can access Recipharm's global manufacturing network, which includes sterile-fill lines, lyophilization capacity, analytical services, and clinical-trial supply capabilities. The parent CDMO's quality-assurance infrastructure — built to serve regulated pharma clients — can help early-stage companies de-risk manufacturing scale-up and regulatory submissions. The fund also draws on the parent's commercial relationships to provide offtake visibility.

EQT acquired Recipharm AB through its EQT IX fund in 2021 in a deal valuing the CDMO at approximately SEK 68 billion. The venture fund operates as a subsidiary of the acquired entity and therefore sits within EQT's portfolio. EQT is not a direct LP in the venture fund, but the fund's capital deployment and strategy ultimately roll up to the private-equity-owned parent's balance sheet and return expectations.

The fund's investment geography includes the Nordic region, continental Europe, and North America. This footprint mirrors the parent CDMO's commercial and manufacturing presence, which spans Sweden, France, Spain, Italy, Germany, the UK, the US, and India. The fund has not publicly disclosed a rigid geographic mandate, but its deal flow is concentrated in markets where the parent company has operational infrastructure.

The Recipharm Foundation is a separate philanthropic entity that supports life-science education and sustainability initiatives. It is not a co-investor in the venture fund and does not participate in investment decisions. The foundation operates independently, though its presence reflects the founding family's broader commitment to the life-science ecosystem in Sweden.